Department of Neurology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Department of Neurology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
World Neurosurg. 2024 Jul;187:e302-e312. doi: 10.1016/j.wneu.2024.04.077. Epub 2024 Apr 23.
Direct carotid-cavernous fistulas (dCCFs) involve the abnormal shunting of blood between the internal carotid artery and the cavernous sinus. The use of covered stents (CSs) has been reported for the treatment of complex carotid artery lesions. However, the efficacy and safety of CS treatment for dCCFs remain controversial. Thus, we performed a systematic review and meta-analysis to evaluate these efficacy and safety endpoints.
A systematic literature review was performed by comprehensively searching the Medline, Embase, and Web of Science databases to identify studies that were related to CS treatment for dCCFs. Then, a meta-analysis was conducted to pool the efficacy and safety outcomes from these studies based on perioperative and follow-up data.
Fourteen noncomparative studies enrolling 156 patients with 160 dCCFs met the inclusion criteria. When analyzing perioperative outcomes, the technical success rate was 98.5% [95% confidence interval (CI), 0.948; 1.000], and the immediate complete occlusion rate was 90.9% (95% CI, 0.862; 0.959). Vasospasm and dissection occurred in 32.2% (95% CI, 0.238; 0.463) and 0.1% (95% CI, 0.000; 0.012) of patients, respectively. The in-stent acute thrombus formation rate was 0.1% (95% CI, 0.000; 0.013). Postoperatively, the mortality rate was 0.1% (95% CI, 0.000; 0.013). Based on available follow-up data, the final complete occlusion and parent artery stenosis rates were 99.3% (95% CI, 0.959; 1.000) and 18.6% (95% CI, 0.125; 0.277), respectively.
CS placement can be used to safely and effectively treat dCCFs. These results provide a reference for future clinical trials.
直接颈动脉-海绵窦瘘(dCCF)涉及颈内动脉和海绵窦之间的血液异常分流。覆膜支架(CS)的使用已被报道用于治疗复杂的颈动脉病变。然而,CS 治疗 dCCF 的疗效和安全性仍存在争议。因此,我们进行了系统评价和荟萃分析,以评估这些疗效和安全性终点。
通过全面检索 Medline、Embase 和 Web of Science 数据库,对与 CS 治疗 dCCF 相关的研究进行系统文献回顾。然后,根据围手术期和随访数据,对这些研究的疗效和安全性结果进行荟萃分析。
纳入的 14 项非对照研究共纳入 156 例 160 例 dCCF 患者。分析围手术期结果时,技术成功率为 98.5%[95%可信区间(CI),0.948;1.000],即刻完全闭塞率为 90.9%(95%CI,0.862;0.959)。血管痉挛和夹层的发生率分别为 32.2%(95%CI,0.238;0.463)和 0.1%(95%CI,0.000;0.012)。支架内急性血栓形成率为 0.1%(95%CI,0.000;0.013)。术后死亡率为 0.1%(95%CI,0.000;0.013)。根据现有随访数据,最终完全闭塞率和母动脉狭窄率分别为 99.3%(95%CI,0.959;1.000)和 18.6%(95%CI,0.125;0.277)。
CS 置入术可安全有效地治疗 dCCF。这些结果为未来的临床试验提供了参考。